Due to a system-wide technology update, we are experiencing extremely high call volume. We appreciate your patience with our operators during this time. Thank you for choosing Fox Chase Cancer Center.
Y. Lynn Wang Joins the Department of Pathology at Fox Chase Cancer Center
PHILADELPHIA (November 26, 2018) – Fox Chase Cancer Center is pleased to announce the hiring of Y. Lynn Wang, MD, PhD, FCAP, as a professor of Pathology.
Clinically, Wang is a board-certified molecular pathologist who specializes in the development and interpretation of molecular and genomic clinical assays including
next-gen sequencing assays. She comes to Fox Chase from the University of Chicago, where she was a professor of Pathology and the founding director of the Genomic and Molecular Pathology Division. She also held appointments as a member of the University of Chicago Medicine Comprehensive Cancer Center. She was an elected officer of the Association for Molecular Pathology.
Wang is also a physician scientist. As part of her transition, the Wang Lab was relocated to Fox Chase from the University of Chicago. As a principal investigator, Wang leads several translational research projects on aberrant signal transduction pathways in B-cell lymphoma and leukemia.
Wang earned her MD from the Beijing Medical University and the University of the State of New York, and her PhD in molecular biology/biochemistry from Brandeis University. She completed postdoctoral research in cancer biology at the Abramson Family Cancer Research Institute at the University of Pennsylvania and, residency in clinical pathology as well as fellowship in molecular genetic pathology at the Hospital of the at the University of Pennsylvania. She served as the director of the Molecular Hematopathology Laboratory at Weill Cornell Medical College from 2002 to 2013 before joining the University of Chicago as a professor.
A widely published physician-scientist, Wang has made many contributions to peer-reviewed medical and scientific literature. Her work on B-cell receptor signaling and ibrutinib resistance have appeared in journals such as New England Journal of Medicine, Blood, Leukemia, JAMA Oncology, British Journal of Hematology, Oncogene, Blood Advances, and many others. She has presented her laboratory findings at numerous national and international meetings.
Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence five consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.
For more information, call 888-369-2427